Abstract

Background/Aims: As chronic hepatitis C virus (HCV) infection is associated with impaired natural killer (NK) cell cytotoxicity, we examined the phenotypes and perforin expression of peripheral blood lymphocytes, as well as the effect of interferon-α2b (IFN-α2b) therapy. Methods: Thirty-three patients had chronic hepatitis C, and of them 12 had been on IFN-α2b treatment. Eleven individuals had been treated earlier with IFN-α2b and completely cured, and eight were HCV carriers with persistently normal serum alanine aminotransferase. Three-colour flow cytometry was used to measure the percentage of CD3 +/−CD8+, CD3+CD4+, γδTcR+, Vδ2 TcR+, Vγ9 TcR+, Vδ1 TcR+, CD3−CD16+, CD3−CD56+, CD19+ and perforin-positive cells. NK cell activity was assessed by single cell cytotoxic and flow cytometric assay. Results: Patients with chronic hepatitis C showed an impaired NK cytotoxicity, decreased percentage of CD3-negative-CD8dim-positive (NK subtype) and Vγ9/Vδ2 TcR+ as well as perforin-positive T lymphocytes, compared to controls and to those who were cured from HCV infection. IFN-α2b increased NK cell cytotoxicity and the percentage of perforin-positive lymphocytes. Conclusions: Our findings suggest that in chronic HCV infection a decreased percentage of CD3 −CD8+, Vγ9/Vδ2 TcR+ and perforin-positive T cells and simultaneous decreased peripheral NK activity may contribute to the impaired cellular immune response and the chronicity of the disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.